O Shaughnessy Asset Management LLC Invests $5.52 Million in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

O Shaughnessy Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 44,819 shares of the specialty pharmaceutical company's stock, valued at approximately $5,519,000. O Shaughnessy Asset Management LLC owned approximately 0.07% of Jazz Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Townsquare Capital LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $220,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Jazz Pharmaceuticals by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,899 shares of the specialty pharmaceutical company's stock valued at $1,326,000 after purchasing an additional 1,729 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Martingale Asset Management L P increased its position in shares of Jazz Pharmaceuticals by 190.2% during the 3rd quarter. Martingale Asset Management L P now owns 5,569 shares of the specialty pharmaceutical company's stock worth $620,000 after purchasing an additional 3,650 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in Jazz Pharmaceuticals by 9.5% during the 3rd quarter. Captrust Financial Advisors now owns 4,965 shares of the specialty pharmaceutical company's stock valued at $553,000 after purchasing an additional 430 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now owns 440,307 shares in the company, valued at $54,487,991.25. This represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,023,305 in the last 90 days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Trading Down 8.9 %

NASDAQ JAZZ traded down $10.78 during trading hours on Friday, hitting $110.04. The company's stock had a trading volume of 2,171,302 shares, compared to its average volume of 755,523. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The firm has a market capitalization of $6.68 billion, a P/E ratio of 15.50, a PEG ratio of 1.04 and a beta of 0.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a fifty day moving average of $132.27 and a 200 day moving average of $123.09.

Analyst Ratings Changes

Several research firms have recently weighed in on JAZZ. Barclays reaffirmed an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Morgan Stanley reissued an "overweight" rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.